Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 USD | -0.42% | -7.05% | +1.72% |
05/06 | VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 | CI |
09/05 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.72% | 34.58M | |
+43.76% | 749B | |
+39.42% | 605B | |
-6.55% | 351B | |
+19.54% | 328B | |
+8.02% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+1.62% | 167B | |
+7.21% | 165B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. Provides Earnings Guidance for the Quarter Ended December 31, 2020